Johnson & Johnson announced two-year Phase 3 data for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor, showing sustained skin clearance in patients with moderate-to-severe plaque psoriasis, especially in sensitive areas like scalp and genitals. At Week 112, 60% of scalp psoriasis and 89% of genital psoriasis patients achieved complete clearance, with a favorable safety profile and no new safety concerns. This marks a significant advancement for treating challenging psoriasis sites that often resist topical treatments. Ongoing studies will further explore ICOTYDE's potential in related inflammatory diseases.
Johnson & Johnson (JNJ) shares trade at USD 259.86 on Pluang as of Oct 02, 2026 16:41 WIB, up 0.46% for the day. The stock's market cap stands at $623.34 billion with a 2.02% dividend yield. Investors show a balanced interest with 58% buy orders and 42% sell orders on the platform, reflecting steady engagement amid the new drug data release.
In 2026, both Johnson & Johnson (J&J) and Merck have seen strong stock gains, but J&J's dividend appears more secure for retirement investors. J&J has a consistent history of annual dividend raises, strong free cash flow, and has already faced its ma...
Bank of America increased price targets for AbbVie to $289 and Johnson & Johnson to $278, maintaining Buy and Neutral ratings respectively. AbbVie is favored due to its strong growth potential, robust pipeline, and attractive valuation at 16 times fo...
Bank of America raised its peak sales forecast for Johnson & Johnson's oral psoriasis drug Icotyde to $4.5 billion, up from $2.4 billion, reflecting increased market share assumptions and a sector rerating favoring defensive stocks. The broker projec...
Johnson & Johnson will announce its third-quarter results on October 13. The company saw a 6.6% revenue increase in Q2 to $25.31 billion, driven by strong sales in its multiple myeloma portfolio and the drug Tremfya. Recent data suggests a significan...
Johnson & Johnson announced new two-year data from a Phase 2/3 study showing that IMAAVY (nipocalimab) provides sustained disease control, improved muscle strength, and reduced corticosteroid use in adolescents with generalized myasthenia gravis (gMG...
